KYMERA THERAPEUTICS INC
NASDAQ: KYMR (Kymera Therapeutics, Inc.)
Last update: 16 hours ago69.93
-2.84 (-3.90%)
| Previous Close | 72.77 |
| Open | 71.95 |
| Volume | 634,833 |
| Avg. Volume (3M) | 958,093 |
| Market Cap | 5,594,331,648 |
| Price / Sales | 127.89 |
| Price / Book | 5.76 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Operating Margin (TTM) | -336.77% |
| Diluted EPS (TTM) | -3.11 |
| Quarterly Revenue Growth (YOY) | 114.80% |
| Total Debt/Equity (MRQ) | 10.98% |
| Current Ratio (MRQ) | 8.49 |
| Operating Cash Flow (TTM) | -234.06 M |
| Levered Free Cash Flow (TTM) | -136.32 M |
| Return on Assets (TTM) | -19.47% |
| Return on Equity (TTM) | -32.17% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Kymera Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | -3.0 |
| Price Volatility | -3.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.30 |
|
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients’ lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 2.50% |
| % Held by Institutions | 104.98% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Avoro Capital Advisors Llc | 30 Sep 2025 | 6,350,000 |
| Atlas Venture Life Science Advisors, Llc | 30 Sep 2025 | 4,896,462 |
| Siren, L.L.C. | 30 Sep 2025 | 3,428,150 |
| Jennison Associates Llc | 30 Sep 2025 | 1,027,739 |
| Driehaus Capital Management Llc | 30 Sep 2025 | 939,094 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 138.00 (BTIG, 97.34%) | Buy |
| Median | 118.50 (69.46%) | |
| Low | 90.00 (Guggenheim, 28.70%) | Buy |
| Average | 117.89 (68.58%) | |
| Total | 18 Buy | |
| Avg. Price @ Call | 84.48 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 15 Jan 2026 | 138.00 (97.34%) | Buy | 71.12 |
| 09 Dec 2025 | 138.00 (97.34%) | Buy | 86.88 | |
| B. Riley Securities | 22 Dec 2025 | 117.00 (67.31%) | Buy | 84.35 |
| RBC Capital | 16 Dec 2025 | 103.00 (47.29%) | Buy | 84.19 |
| Mizuho | 11 Dec 2025 | 120.00 (71.60%) | Buy | 87.81 |
| Stephens & Co. | 11 Dec 2025 | 110.00 (57.30%) | Buy | 87.81 |
| JP Morgan | 10 Dec 2025 | 125.00 (78.75%) | Buy | 89.89 |
| B of A Securities | 09 Dec 2025 | 112.00 (60.16%) | Buy | 86.88 |
| Barclays | 09 Dec 2025 | 119.00 (70.17%) | Buy | 86.88 |
| 05 Nov 2025 | 70.00 (0.10%) | Buy | 59.89 | |
| Citigroup | 09 Dec 2025 | 110.00 (57.30%) | Buy | 86.88 |
| HC Wainwright & Co. | 09 Dec 2025 | 134.00 (91.62%) | Buy | 86.88 |
| 05 Nov 2025 | 84.00 (20.12%) | Buy | 59.89 | |
| Jefferies | 09 Dec 2025 | 122.00 (74.46%) | Buy | 86.88 |
| Leerink Partners | 09 Dec 2025 | 118.00 (68.74%) | Buy | 86.88 |
| Morgan Stanley | 09 Dec 2025 | 127.00 (81.61%) | Buy | 86.88 |
| Oppenheimer | 09 Dec 2025 | 120.00 (71.60%) | Buy | 86.88 |
| Piper Sandler | 09 Dec 2025 | 125.00 (78.75%) | Buy | 86.88 |
| Truist Securities | 09 Dec 2025 | 116.00 (65.88%) | Buy | 86.88 |
| 26 Nov 2025 | 80.00 (14.40%) | Buy | 67.86 | |
| Wells Fargo | 09 Dec 2025 | 116.00 (65.88%) | Buy | 86.88 |
| 05 Nov 2025 | 69.00 (-1.33%) | Buy | 59.89 | |
| Guggenheim | 03 Nov 2025 | 90.00 (28.70%) | Buy | 59.72 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ESPOSITO PAMELA | - | 68.14 | -5,500 | -374,770 |
| Aggregate Net Quantity | -5,500 | |||
| Aggregate Net Value ($) | -374,770 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 68.14 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| ESPOSITO PAMELA | Director | 20 Jan 2026 | Automatic sell (-) | 5,500 | 68.14 | 374,770 |
| ESPOSITO PAMELA | Director | 20 Jan 2026 | Option execute | 5,500 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |